Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia

Key Points

• To evaluate the clinical utility of NGS-based measurable residual disease testing for B-cell acute lymphoblastic leukaemia.
• Implemented NGS-based MRD testing since 2018.
• Utilized in routine patient care for monitoring.
• Focused on patients with B-cell acute lymphoblastic leukaemia.
• Demonstrated clinical utility for disease monitoring.
• Established effectiveness in detecting measurable residual disease.

Abstract